- Policy
- Indications for Forxiga include CHF
- by Kim, Jung-Ju Jan 15, 2021 06:10am
- As the indication for AstraZeneca’s SGLT-2 inhibitor Forxiga 10mg (Dapagliflozin) has been extended to chronic heart failure, it is clearly covered in the benefit. On the 12th, the MOHW announced a partial amendment to the 'Pharmaceutical Reimbursement Listing Standard and Method', which establishes the reimbursement standards for additio
- Opinion
- [Reporter's View] Activation of the Generic Substitution
- by Kim, Jung-Ju Jan 14, 2021 01:23pm
- At the beginning of the year, small shops and large companies make actionable plans for the next year. The government plans the budget as well. In addition, the government divides and executes policy projects more detailed and strategically because administrative procedures and processes are more demanding than private enterprises. Accord
- Company
- Stepped pricing to put pressure for patent challenge
- by Kim, Jin-Gu Jan 14, 2021 06:16am
- The stepped drug pricing system, revived since last July, seems to have affected the pharmaceutical industry’s patent strategy. The pricing system would create a structure to naturally diminish the drug pricing competitiveness in other companies, when 20 or more companies simultaneously and successfully challenge the patent. Pharmaceu
- Policy
- COVID-19 vaccine budget KRW 857.1 Bln received
- by Kim, Jung-Ju Jan 14, 2021 06:15am
- The South Korean health authority is fully readying for COVID-19 vaccination starting off from February as they have first secured the budget for the vaccine purchase and expenditure for inoculation. The Korea Disease Control and Prevention Agency (KDCA) announced on Jan. 12 the vaccine purchasing budget and inoculation expense budget of
- Policy
- There is progress in introducing additional COVID-19 vaccine
- by Lee, Jeong-Hwan Jan 14, 2021 06:15am
- Prime Minister Chung Sye-kyun announced that significant progress has been made in introducing additional vaccines from other platforms, including Pfizer, Moderna, AstraZeneca, Janssen, and others regarding the COVID-19 vaccine. Although the spread of COVID-19 has recently slowed, he has been wary of hasty measures to mitigate quarantine.
- Policy
- All citizens will be vaccinated free of charge
- by Lee, Jeong-Hwan Jan 14, 2021 06:15am
- President Moon Jae-in promised free vaccination for all citizens according to the priority of the COVID-19 vaccine at the New Year's address on the 11th. It also announced a plan to strengthen vaccine sovereignty with the domestic COVID-19 vaccine, and to transparently disclose the entire process of licensing, including the safety and e
- Policy
- MFDS OK's removing “redundant” narcotics return approval
- by Lee, Jeong-Hwan Jan 13, 2021 06:12am
- The Ministry of Food and Drug Safety (MFDS) and the National Assembly Expert Committee Office approved of a bill to remove the MFDS narcotics pre-return approval procedure. The bill received the nod prior to the National Assembly Health and Welfare Committee’s review. When it is passed, the pharmacists’ convenience in returning the narcoti
- Company
- JW Pharma is speeding up the development of Dumirox·Actemra
- by Jan 13, 2021 06:12am
- Dumirox and Actemra, which are monopolized by JW Pharma's domestic development and copyright, are emerging as a possible treatment for COVID-19 On the 8th, the MFDS approved sponsor-investigator trials for patients with COVID-19 of Dumirox 100mg (Fluvoxamine maleate), an antidepressant drug. With the approval of this clinical plan, AMC
- Company
- Sanofi financially supports adolescent Dupixent users
- by Jan 13, 2021 06:11am
- On Jan. 11, Sanofi Aventis Korea (President Kay Bae) presented a patient drug expense support program to partially cover the cost of Dupixent Prefilled injection 200 mg (dupilumab) prescribed to adolescent patient with atopic dermatitis. The program aims to contribute in improving the patients’ quality of life by financially supporting
- Company
- Ferring & Chong Kun Dang signed a contract for Nocdurna
- by Jan 13, 2021 06:11am
- Ferring Korea and Chong Kun Dang announced on the 11th that they have signed a joint sales contract for 'Nocdurna Sublingual Tab (Desmopressin acetate)', a treatment for nocturia. Following the signing of this contract, Ferring Korea will be in charge of marketing for general hospitals from the 18th, and Chong Kun-dang will be in charge of
